You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the DHIVY (carbidopa; levodopa) Drug Profile, 2024 PDF Report in the Report Store ~

DHIVY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Dhivy patents expire, and what generic alternatives are available?

Dhivy is a drug marketed by Avion Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has seven patent family members in six countries.

The generic ingredient in DHIVY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Dhivy

A generic version of DHIVY was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28th, 1992.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DHIVY?
  • What are the global sales for DHIVY?
  • What is Average Wholesale Price for DHIVY?
Summary for DHIVY
International Patents:7
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for DHIVY
What excipients (inactive ingredients) are in DHIVY?DHIVY excipients list
DailyMed Link:DHIVY at DailyMed
Drug patent expirations by year for DHIVY
Drug Prices for DHIVY

See drug prices for DHIVY

Pharmacology for DHIVY

US Patents and Regulatory Information for DHIVY

DHIVY is protected by five US patents.

Patents protecting DHIVY

Levodopa fractionated dose composition and use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE

Levodopa fractionated dose composition and use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING SEGMENTS OF A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG, EACH SEGMENT HAVING CARBIDOPA—6.25 MG/LEVODOPA—25 MG

Levodopa fractionated dose composition and use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG

Levodopa fractionated dose composition and use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avion Pharms DHIVY carbidopa; levodopa TABLET;ORAL 214869-001 Nov 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Avion Pharms DHIVY carbidopa; levodopa TABLET;ORAL 214869-001 Nov 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Avion Pharms DHIVY carbidopa; levodopa TABLET;ORAL 214869-001 Nov 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for DHIVY

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Amneal Pharma Europe Ltd Numient levodopa, carbidopa EMEA/H/C/002611
Symptomatic treatment of adult patients with Parkinson’s disease
Withdrawn no no no 2015-11-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for DHIVY

See the table below for patents covering DHIVY around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3773532 COMPOSITION DE DOSE FRACTIONNÉE DE LÉVODOPA ET UTILISATION (LEVODOPA FRACTIONATED DOSE COMPOSITION AND USE) ⤷  Sign Up
Japan 2021517128 レボドパ分割用量組成物および使用 ⤷  Sign Up
Canada 3095341 COMPOSITION DE DOSE FRACTIONNEE DE LEVODOPA ET UTILISATION (LEVODOPA FRACTIONATED DOSE COMPOSITION AND USE) ⤷  Sign Up
China 111954523 左旋多巴分次剂量组合物及用途 (Levodopa fractionated dose composition and use) ⤷  Sign Up
Brazil 112020017422 composição de dose fracionada de levodopa e uso ⤷  Sign Up
Japan 2022133449 レボドパ分割用量組成物および使用 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2019191353 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.